{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:22:24Z","timestamp":1792466544608,"version":"4.5.0"},"reference-count":116,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["jme.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Bone-forming approaches to treat patients with severe osteoporosis are effective, but treatment options are limited, and there is an unmet clinical need for additional drugs. This review discusses two novel and advanced anabolic therapeutic concepts that have successfully completed phase 3 trials. Romosozumab is a monoclonal antibody that targets the Wnt inhibitor sclerostin. Two phase 3 trials (FRAME and ARCH) of romosozumab for the treatment of postmenopausal osteoporosis have been completed. Both trials successfully reached their primary endpoint by reducing vertebral fractures by 75% compared to placebo (FRAME trial) and 48% compared to alendronate (ARCH trial), respectively. Abaloparatide is a PTH-related protein (PTHrP) analog that has displayed bone anabolic activity. In the phase 3 ACTIVE trial, abaloparatide was compared to placebo and teriparatide for 18 months in postmenopausal women who had already experienced an osteoporotic fracture. Abaloparatide successfully reduced the rate of new vertebral fractures by 86% compared to placebo. Furthermore, abaloparatide achieved greater BMD increases at all measured sites compared to both placebo and teriparatide. Based on these results, abaloparatide was FDA approved in April 2017. This review discusses available data of both agents with regard to efficacy and safety as well as their possible future application.<\/jats:p>","DOI":"10.1530\/jme-18-0173","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:55:06Z","timestamp":1536828906000},"page":"R145-R154","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-6","source":"Crossref","is-referenced-by-count":43,"title":["Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin"],"prefix":"10.1530","volume":"62","author":[{"given":"Tilman D","family":"Rachner","sequence":"first","affiliation":[{"name":"1Department of Medicine III, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"2Center for Healthy Aging, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"2Center for Healthy Aging, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany"},{"name":"4Center for Regenerative Therapies Dresden, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"2Center for Healthy Aging, Technische Universit\u00e4t Dresden Medical Center, Dresden, Germany"},{"name":"3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref161","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy","volume":"15","year":"2017","journal-title":"Current Osteoporosis Reports"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: an update","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00223-017-0258-3","article-title":"Romosozumab treatment converts trabecular rods into trabecular plates in male cynomolgus monkeys","volume":"101","year":"2017","journal-title":"Calcified Tissue International"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","year":"2012","journal-title":"Nature Genetics"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of Romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","year":"2015","journal-title":"Bone"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrendo.2017.136","article-title":"Romosozumab-on track or derailed?","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref871","first-page":"S539","article-title":"BIM-44058, a novel PTHrP analog, increases bone formation but not bone resorption histomorphometric parameters in old ovariectomized cynomolgus monkeys","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","year":"2016","journal-title":"Endocrinology"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","year":"2012","journal-title":"Nature Genetics"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2010.05767.x","article-title":"Use of bisphosphonates in the management of postmenopausal osteoporosis","volume":"1218","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","year":"2002","journal-title":"Journal of Medical Genetics"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI83731","article-title":"Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia","volume":"127","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","year":"2002","journal-title":"American Journal of Medical Genetics"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI83731","article-title":"Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia","volume":"127","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"ref291","first-page":"S539","article-title":"BIM-44058, a novel PTHrP analog, increases bone formation but not bone resorption histomorphometric parameters in old ovariectomized cynomolgus monkeys","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00018-004-4462-3","article-title":"G-protein signaling: back to the future","volume":"62","year":"2005","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocd.2012.11.013","article-title":"Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk","volume":"16","year":"2013","journal-title":"Journal of Clinical Densitometry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","year":"2001","journal-title":"Human Molecular Genetics"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14310\/horm.2002.1308","article-title":"Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis","volume":"10","year":"2011","journal-title":"Hormones"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy","volume":"15","year":"2017","journal-title":"Current Osteoporosis Reports"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","year":"2017a","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-sc (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","year":"2017","journal-title":"Bone"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbrc.2004.11.069","article-title":"Parathyroid hormone and parathyroid hormone-related peptide, and their receptors","volume":"328","year":"2005","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-sc (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","year":"2017","journal-title":"Bone"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","article-title":"Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption","volume":"29","year":"2018","journal-title":"Osteoporosis International"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocd.2012.11.013","article-title":"Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk","volume":"16","year":"2013","journal-title":"Journal of Clinical Densitometry"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","year":"2002","journal-title":"American Journal of Human Genetics"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling-mechanistic insights and therapeutic prospects","volume":"11","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","year":"2002","journal-title":"American Journal of Human Genetics"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","article-title":"One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats","volume":"95","year":"2017b","journal-title":"Bone"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1210\/jc.2003-030201","article-title":"Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal","volume":"88","year":"2003","journal-title":"Journal of Clinical Metabolism and Endocrinology"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of Romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","year":"2015","journal-title":"Bone"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","year":"2009","journal-title":"Bone"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","year":"2003","journal-title":"Bone"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/joim.12368","article-title":"The WNT system: background and its role in bone","volume":"277","year":"2015","journal-title":"Journal of Internal Medicine"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbrc.2004.11.069","article-title":"Parathyroid hormone and parathyroid hormone-related peptide, and their receptors","volume":"328","year":"2005","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of Abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","year":"2017a","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00018-004-4462-3","article-title":"G-protein signaling: back to the future","volume":"62","year":"2005","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/joim.12368","article-title":"The WNT system: background and its role in bone","volume":"277","year":"2015","journal-title":"Journal of Internal Medicine"},{"key":"ref681","first-page":"1532","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","year":"2017c","journal-title":"New England Journal of Medicine"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","year":"2009","journal-title":"Bone"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","year":"2017","journal-title":"Bone"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling-mechanistic insights and therapeutic prospects","volume":"11","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00223-017-0258-3","article-title":"Romosozumab treatment converts trabecular rods into trabecular plates in male cynomolgus monkeys","volume":"101","year":"2017","journal-title":"Calcified Tissue International"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of Abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","year":"2017a","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ajp.20715","article-title":"Skeletal health: primate model of postmenopausal osteoporosis","volume":"71","year":"2009","journal-title":"American Journal of Primatology"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","year":"2002","journal-title":"American Journal of Medical Genetics"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrendo.2017.136","article-title":"Romosozumab-on track or derailed?","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","article-title":"Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption","volume":"29","year":"2018","journal-title":"Osteoporosis International"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: an update","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","year":"2017","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: the foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody Romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","year":"2016","journal-title":"Endocrinology"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","year":"2017a","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of Blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","article-title":"One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats","volume":"95","year":"2017b","journal-title":"Bone"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension","volume":"5","year":"2017","journal-title":"Lancet Diabetes Endocrinology"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","year":"2001","journal-title":"Cell"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","year":"2001","journal-title":"Cell"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","year":"2017","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with Romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","year":"2017","journal-title":"Bone"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: the foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","year":"2001","journal-title":"Human Molecular Genetics"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref101","first-page":"1532","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","year":"2017c","journal-title":"New England Journal of Medicine"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of Blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ajp.20715","article-title":"Skeletal health: primate model of postmenopausal osteoporosis","volume":"71","year":"2009","journal-title":"American Journal of Primatology"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","year":"2017b","journal-title":"Mayo Clinic Proceedings"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension","volume":"5","year":"2017","journal-title":"Lancet Diabetes Endocrinology"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with Romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1060028017748649","article-title":"Abaloparatide: review of a next-generation parathyroid hormone agonist","volume":"52","year":"2018","journal-title":"Annals of Pharmacotherapy"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","year":"2017b","journal-title":"Mayo Clinic Proceedings"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2010.05767.x","article-title":"Use of bisphosphonates in the management of postmenopausal osteoporosis","volume":"1218","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14310\/horm.2002.1308","article-title":"Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis","volume":"10","year":"2011","journal-title":"Hormones"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","year":"2003","journal-title":"Bone"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1210\/jc.2003-030201","article-title":"Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal","volume":"88","year":"2003","journal-title":"Journal of Clinical Metabolism and Endocrinology"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1060028017748649","article-title":"Abaloparatide: review of a next-generation parathyroid hormone agonist","volume":"52","year":"2018","journal-title":"Annals of Pharmacotherapy"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","year":"2002","journal-title":"Journal of Medical Genetics"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody Romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"}],"container-title":["Journal of Molecular Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/jme.bioscientifica.com\/view\/journals\/jme\/62\/2\/JME-18-0173.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jme.bioscientifica.com\/downloadpdf\/journals\/jme\/62\/2\/JME-18-0173.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:37Z","timestamp":1784555617000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/jme\/article\/62\/2\/R145-R154\/14317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":116,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/jme-18-0173","relation":{},"ISSN":["0952-5041","1479-6813"],"issn-type":[{"value":"0952-5041","type":"print"},{"value":"1479-6813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}